Literature DB >> 19965551

Tissue-advanced glycation end product concentration in dialysis patients.

Natasha J McIntyre1, Lindsay J Chesterton, Stephen G John, Helen J Jefferies, James O Burton, Maarten W Taal, Richard J Fluck, Christopher W McIntyre.   

Abstract

BACKGROUND AND OBJECTIVES: Tissue-advanced glycation end products (AGE) are a measure of cumulative metabolic stress. Assessment of tissue AGE by skin autofluoresence (AF) correlates well with cardiovascular outcomes in hemodialysis (HD) patients. This study aimed to measure and compare tissue AGE levels in HD and peritoneal dialysis (PD) patients and to evaluate the impact of systemic PD glucose exposure. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Tissue AGE were measured in 115 established dialysis patients (62 HD and 53 PD) using a cutaneous AF device (AGE Reader; DiagnOptics). Values were compared with an age-matched non-chronic kidney disease database. Review of all previous PD solution delivery/prescription data determined PD glucose exposure.
RESULTS: PD patients were similar in age to HD patients but had a shorter dialysis vintage. There were no differences in ischemic heart disease or smoking history, statin or angiotensin-converting enzyme inhibitor (ACEi) use, lipids, biochemistry, or prevalence of diabetes. More than 90% of both groups had met current dialysis adequacy targets. Skin AF values in PD and HD patients were similar and strongly correlated with historical PD glucose exposure. Skin AF correlated with age in both groups but with dialysis vintage only in PD patients
CONCLUSIONS: Cumulative metabolic stress and transient hyperglycemia results in grossly elevated levels of tissue AGE in dialysis patients. In PD patients, this high level of AGE deposition is associated with historical glucose exposure. This observation provides a previously unappreciated potential link between PD exposure to glucose and systemic cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19965551      PMCID: PMC2801641          DOI: 10.2215/CJN.05350709

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  31 in total

1.  Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage.

Authors:  T Nishikawa; D Edelstein; X L Du; S Yamagishi; T Matsumura; Y Kaneda; M A Yorek; D Beebe; P J Oates; H P Hammes; I Giardino; M Brownlee
Journal:  Nature       Date:  2000-04-13       Impact factor: 49.962

Review 2.  Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management.

Authors:  P S Parfrey
Journal:  Nephrol Dial Transplant       Date:  2000       Impact factor: 5.992

Review 3.  Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links.

Authors:  S Vasan; P G Foiles; H W Founds
Journal:  Expert Opin Investig Drugs       Date:  2001-11       Impact factor: 6.206

Review 4.  Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes.

Authors:  Thoralf Wendt; Loredana Bucciarelli; Wu Qu; Yan Lu; Shi Fang Yan; David M Stern; Ann Marie Schmidt
Journal:  Curr Atheroscler Rep       Date:  2002-05       Impact factor: 5.113

Review 5.  From life to death--the struggle between chemistry and biology during aging: the Maillard reaction as an amplifier of genomic damage.

Authors:  J W Baynes
Journal:  Biogerontology       Date:  2000       Impact factor: 4.277

Review 6.  Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond.

Authors:  Shi Fang Yan; Ravichandran Ramasamy; Yoshifumi Naka; Ann Marie Schmidt
Journal:  Circ Res       Date:  2003-12-12       Impact factor: 17.367

Review 7.  Glucose degradation products in peritoneal dialysis fluids: do they harm?

Authors:  Janusz Witowski; Achim Jörres; Katarzyna Korybalska; Krzysztof Ksiazek; Justyna Wisniewska-Elnur; Thorsten O Bender; Jutta Passlick-Deetjen; Andrzej Breborowicz
Journal:  Kidney Int Suppl       Date:  2003-05       Impact factor: 10.545

Review 8.  Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes.

Authors:  Doron Aronson
Journal:  J Hypertens       Date:  2003-01       Impact factor: 4.844

9.  Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults.

Authors:  Richard D Semba; Samer S Najjar; Kai Sun; Edward G Lakatta; Luigi Ferrucci
Journal:  Am J Hypertens       Date:  2008-11-20       Impact factor: 2.689

Review 10.  Oxidative stress in end-stage renal disease: an emerging threat to patient outcome.

Authors:  Francesco Locatelli; Bernard Canaud; Kai-Uwe Eckardt; Peter Stenvinkel; Christoph Wanner; Carmine Zoccali
Journal:  Nephrol Dial Transplant       Date:  2003-07       Impact factor: 5.992

View more
  21 in total

1.  Evaluation of advanced glycation end products accumulation, using skin autofluorescence, in CKD and dialysis patients.

Authors:  Mihaela Oleniuc; Adalbert Schiller; Irina Secara; Mihai Onofriescu; Simona Hogas; Mugurel Apetrii; Dimitrie Siriopol; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2011-12-10       Impact factor: 2.370

2.  "NEPP" peritoneal dialysis regimen has beneficial effects on plasma CEL and 3-DG, but not pentosidine, CML, and MGO.

Authors:  Caatje Y le Poole; Frans J van Ittersum; Rob M Valentijn; Tom Teerlink; Bengt Lindholm; Piet M Ter Wee; Casper G Schalkwijk
Journal:  Perit Dial Int       Date:  2011-05-31       Impact factor: 1.756

Review 3.  Uremic Toxicity of Advanced Glycation End Products in CKD.

Authors:  Andréa E M Stinghen; Ziad A Massy; Helen Vlassara; Gary E Striker; Agnès Boullier
Journal:  J Am Soc Nephrol       Date:  2015-08-26       Impact factor: 10.121

4.  Advanced glycation end products, aortic stiffness, and wave reflection in peritoneal dialysis as compared to hemodialysis.

Authors:  Fabrice Mac-Way; Véronique Couture; Mihai S Utescu; Sophie Ignace; Sacha A De Serres; Renée-Claude Loignon; Karine Marquis; Richard Larivière; Mohsen Agharazii
Journal:  Int Urol Nephrol       Date:  2013-11-17       Impact factor: 2.370

5.  Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3.

Authors:  Natasha J McIntyre; Richard J Fluck; Christopher W McIntyre; Maarten W Taal
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-01       Impact factor: 8.237

Review 6.  Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms.

Authors:  Alin Stirban; Thomas Gawlowski; Michael Roden
Journal:  Mol Metab       Date:  2013-12-07       Impact factor: 7.422

Review 7.  Reducing cardiometabolic risk in peritoneal dialysis patients: role of the dialysis solution.

Authors:  Clifford J Holmes
Journal:  J Diabetes Sci Technol       Date:  2009-11-01

Review 8.  Skin Autofluorescence - A Non-invasive Measurement for Assessing Cardiovascular Risk and Risk of Diabetes.

Authors:  Alin Stirban; Lutz Heinemann
Journal:  Eur Endocrinol       Date:  2014-08-28

9.  Tissue advanced glycation end products (AGEs), measured by skin autofluorescence, predict mortality in peritoneal dialysis.

Authors:  Dimitrie Siriopol; Simona Hogas; Gabriel Veisa; Irina Mititiuc; Carmen Volovat; Mugurel Apetrii; Mihai Onofriescu; Irina Busila; Mihaela Oleniuc; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2014-11-26       Impact factor: 2.370

Review 10.  Peritoneal changes in patients on long-term peritoneal dialysis.

Authors:  Raymond T Krediet; Dirk G Struijk
Journal:  Nat Rev Nephrol       Date:  2013-05-14       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.